Sosei Considers Future Of Fibromyalgia Candidate AD 337 After Failed Phase II Trial
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Sosei Group is not ready to give up on its fibromyalgia candidate AD 337 after a Phase II study failed to meet its primary endpoint, the firm announced Sept. 18